Developer docs
API playgroundTry for free, no card

Search company profiles

KeyBioscience

Full company profile

uuid003o5ug

Namestring
KeyBioscience
Legal namestring
KeyBioscience AG
Company typeenum
Private
Founded yearint
2011
Descriptiontext

KeyBioscience AG is a Swiss clinical-stage biopharmaceutical company headquartered in Lugano, Switzerland, focused on discovering and developing novel peptide therapeutics for metabolic disorders. Founded in October 2011 originally as NUCo-Development — a joint venture between Nordic Bioscience and Unigene — the entity was renamed KeyBioscience in 2013 after Nordic Bioscience acquired Unigene's stake following Unigene's bankruptcy. The company now operates as a subsidiary of Nordic Bioscience.

The company's core technology is the DACRA (Dual Amylin and Calcitonin Receptor Agonist) peptide platform, which engineers peptides derived from naturally occurring variants in non-mammalian species (fish, birds, amphibians) where amylin and calcitonin functions are combined in a single peptide. The platform applies a battery of profiling assays measuring potency on amylin and calcitonin receptors — including cAMP and β-arrestin signaling, competitive ligand binding studies, and counter-screening for off-target effects on CGRP and adrenomedullin receptors — to engineer DACRAs with prolonged receptor activation enabling once-weekly dosing. KeyBioscience identifies lead candidates internally through this platform and has advanced three peptides into clinical development: KBP-042 for Type 2 Diabetes, KBP-089 and KBP-056 (both licensed to Eli Lilly in 2017), and the current lead KBP-336, a long-acting once-weekly injectable being developed for metabolic osteoarthritis.

KeyBioscience operates on a licensing and co-development revenue model with no commercial products on the market. Two peptides (KBP-089 and KBP-056) were licensed to Eli Lilly in 2017 under a strategic partnership that has since yielded a second-generation once-weekly Lilly-KeyBio QW DACRA in clinical development for obesity. Revenue is generated through licensing agreements, development and regulatory milestones, and potential future royalties on commercialized products. The company is private, with no public listing, no disclosed funding rounds, and no revenue figures in the public record. Operational continuity is supported through its parent Nordic Bioscience.

Short descriptiontext

KeyBioscience is a Swiss clinical-stage biopharmaceutical company that discovers and develops novel peptide therapeutics (DACRAs) for metabolic disorders, including Type 2 Diabetes, obesity, and osteoarthritis, partnering with Eli Lilly to advance its pipeline.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersLugano, Switzerland
HQ citystring
Lugano
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
peptide therapeutics, metabolic disorder drugs, DACRA technology, clinical-stage biopharmaceuticals, obesity therapeutics
Industry3 codes
PRIMARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIACAD
Endocrinology & Metabolic Specialty Pharmaceuticals
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Peptide Therapeutics for Metabolic Disorders
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Licensing and Co-development Agreements
TypeLicensing Royalties
Description

KeyBioscience develops novel peptide therapeutics internally and out-licenses development candidates to pharmaceutical partners. Revenue is generated through upfront payments, milestone payments tied to development and regulatory achievements, and potential royalties on commercialized products.

keybioscience.com
2Strategic Partnerships
TypeLicensing Royalties
Description

Partnership with Eli Lilly for DACRA development represents a key revenue stream through development milestones and potential future royalties on approved products.

keybioscience.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

KeyBioscience is a clinical-stage biopharmaceutical company that discovers and develops novel peptide therapeutics for metabolic disorders. Its proprietary DACRA (Dual Amylin and Calcitonin Receptor Agonist) platform engineers peptides with prolonged receptor activation, enabling once-weekly injectable dosing for indications including Type 2 Diabetes, obesity, and metabolic osteoarthritis. Development candidates are out-licensed to large pharmaceutical partners (notably Eli Lilly) for clinical development and commercialization.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • KBP-336 is the most potent DACRA identified to date, selected for clinical development based on highly promising potency, stability, and durability of response in model systems
Product overview1 text field

KeyBioscience is a biopharmaceutical company focused on discovering and developing novel peptide therapeutics for metabolic disorders. The company's core offering is its DACRA (Dual Amylin and Calcitonin Receptor Agonists) peptide platform, which leverages an extensive profiling platform inspired by naturally occurring peptide variants. The platform has yielded multiple product candidates: KBP-042 (first-generation for Type 2 Diabetes), KBP-089 and KBP-056 (for obesity and osteoarthritis), KBP-336 (long-acting once-weekly injectable for metabolic osteoarthritis currently in clinical development), and the Lilly-KeyBio QW DACRA (licensed to Eli Lilly for obesity). Three peptides have entered clinical development for Type 2 Diabetes, obesity, and osteoarthritis, with two licensed to Eli Lilly in 2017.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2017-01-01
Description

Strategic partnership established in summer 2017 to develop the first Dual Amylin Calcitonin Receptor Agonist (DACRA) for type 2 diabetes as a once-daily injectable. KeyBioscience licensed two peptides (KBP-089 and KBP-056) to Eli Lilly. A second generation of the Lilly-KeyBio QW DACRA is now in clinical development for obesity. The partnership bore fruit with the announcement of the Lilly-KeyBio QW DACRA clinical asset in spring 2022.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2011-01-01
Description

Nordic Bioscience co-founded KeyBioscience (originally NUCo-Development) in October 2011 as an equal venture with Unigene. Nordic Bioscience provided financial support and has grown to be a partner to some of the largest drug developers in the world. Following Unigene's bankruptcy in 2013, Nordic Bioscience acquired Unigene's stake, transforming NUCo-Development into KeyBioscience.

3Unigene
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2011-01-01
Description

Original founding partner in NUCo-Development venture established October 2011 with Nordic Bioscience. Unigene contributed intellectual property to the partnership. Unigene faced bankruptcy in summer 2013, after which Nordic Bioscience acquired Unigene's stake.

keybioscience.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers7 records
TypeBroad incumbent
Description

Eli Lilly is KeyBioscience's strategic partner and the dominant incumbent in metabolic therapeutics, with the leading GLP-1/incretin franchise (tirzepatide) and its own obesity pipeline. Lilly provides the comparator benchmark for DACRA efficacy and the likely commercialization channel for licensed KeyBioscience assets.

TypeEmerging player
Description

Rhythm Pharmaceuticals is a commercial-stage company focused on rare metabolic diseases (MC4R pathway) with an MC4R agonist franchise. It shares with KeyBioscience a focus on peptide/receptor-agonist mechanisms targeting metabolic disease pathophysiology, although in a different receptor niche.

TypeEmerging player
Description

Vivani Medical (formerly Vivani + Cortigent) develops long-acting peptide-based implants for chronic metabolic disease. Its long-duration peptide delivery approach and metabolic indication focus intersect with KeyBioscience's once-weekly DACRA strategy for obesity and related disorders.

TypeDirect peer
Description

Zealand Pharma is a clinical-stage peptide therapeutics company with a leading amylin analog program for obesity and metabolic disease, making it the closest direct competitor to KeyBioscience's DACRA platform in mechanism, indication space, and development stage.

TypeBroad incumbent
Description

Novo Nordisk is the global incumbent in diabetes and obesity therapeutics, anchored by its GLP-1 franchise (semaglutide) and actively developing amylin and dual-agonist candidates. It defines the competitive bar that any DACRA-style therapy must clear to capture commercial value.

TypeEmerging player
Description

MBX Biosciences is a clinical-stage peptide therapeutics company developing long-acting peptides for endocrine and metabolic disorders. Its emphasis on engineered, long-duration peptide analogs parallels KeyBioscience's prolonged-activation DACRA design philosophy.

TypeEmerging player
Description

Crinetics is a clinical-stage company developing oral peptide/non-peptide agonists for endocrine and metabolic indications, including acromegaly and hyperinsulinism. Its peptide-based mechanism and metabolic/endocrine indication focus overlap directly with KeyBioscience's metabolic peptide strategy.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

KeyBioscience

Peptide Therapeutics for Metabolic Disorderskeybioscience.com

KeyBioscience is a Swiss clinical-stage biopharmaceutical company that discovers and develops novel peptide therapeutics (DACRAs) for metabolic disorders, including Type 2 Diabetes, obesity, and osteoarthritis, partnering with Eli Lilly to advance its pipeline.

What KeyBioscience does

KeyBioscience AG is a Swiss clinical-stage biopharmaceutical company headquartered in Lugano, Switzerland, focused on discovering and developing novel peptide therapeutics for metabolic disorders. Founded in October 2011 originally as NUCo-Development — a joint venture between Nordic Bioscience and Unigene — the entity was renamed KeyBioscience in 2013 after Nordic Bioscience acquired Unigene's stake following Unigene's bankruptcy. The company now operates as a subsidiary of Nordic Bioscience.

The company's core technology is the DACRA (Dual Amylin and Calcitonin Receptor Agonist) peptide platform, which engineers peptides derived from naturally occurring variants in non-mammalian species (fish, birds, amphibians) where amylin and calcitonin functions are combined in a single peptide. The platform applies a battery of profiling assays measuring potency on amylin and calcitonin receptors — including cAMP and β-arrestin signaling, competitive ligand binding studies, and counter-screening for off-target effects on CGRP and adrenomedullin receptors — to engineer DACRAs with prolonged receptor activation enabling once-weekly dosing. KeyBioscience identifies lead candidates internally through this platform and has advanced three peptides into clinical development: KBP-042 for Type 2 Diabetes, KBP-089 and KBP-056 (both licensed to Eli Lilly in 2017), and the current lead KBP-336, a long-acting once-weekly injectable being developed for metabolic osteoarthritis.

KeyBioscience operates on a licensing and co-development revenue model with no commercial products on the market. Two peptides (KBP-089 and KBP-056) were licensed to Eli Lilly in 2017 under a strategic partnership that has since yielded a second-generation once-weekly Lilly-KeyBio QW DACRA in clinical development for obesity. Revenue is generated through licensing agreements, development and regulatory milestones, and potential future royalties on commercialized products. The company is private, with no public listing, no disclosed funding rounds, and no revenue figures in the public record. Operational continuity is supported through its parent Nordic Bioscience.

KeyBioscience firmographics

Firmographics
Name
KeyBioscience
Legal name
KeyBioscience AG
Website
https://keybioscience.com
Company type
Private
Founded year
2011
Operating status
Operating
Headcount range
1–10 employees
Short description
KeyBioscience is a Swiss clinical-stage biopharmaceutical company that discovers and develops novel peptide therapeutics (DACRAs) for metabolic disorders, including Type 2 Diabetes, obesity, and osteoarthritis, partnering with Eli Lilly to advance its pipeline.
Ownership category
akta.pro rank

KeyBioscience industry classification

Industry
Product category
Peptide Therapeutics for Metabolic Disorders
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIACAD
Endocrinology & Metabolic Specialty Pharmaceuticals

Keywords

  • Peptide therapeutics
  • Metabolic disorder drugs
  • DACRA technology
  • Clinical-stage biopharmaceuticals
  • Obesity therapeutics

Where KeyBioscience is headquartered

Location

Headquarters

HQ city
Lugano
HQ country
Switzerland
HQ region
Europe

Offices1 record

Markets served

KeyBioscience business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Revenue model

  1. Licensing and Co-development Agreements: KeyBioscience develops novel peptide therapeutics internally and out-licenses development candidates to pharmaceutical partners. Revenue is generated through upfront payments, milestone payments tied to development and regulatory achievements, and potential royalties on commercialized products.
  2. Strategic Partnerships: Partnership with Eli Lilly for DACRA development represents a key revenue stream through development milestones and potential future royalties on approved products.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels2 records

KeyBioscience product offering

Product offering

Core offering

KeyBioscience is a clinical-stage biopharmaceutical company that discovers and develops novel peptide therapeutics for metabolic disorders. Its proprietary DACRA (Dual Amylin and Calcitonin Receptor Agonist) platform engineers peptides with prolonged receptor activation, enabling once-weekly injectable dosing for indications including Type 2 Diabetes, obesity, and metabolic osteoarthritis. Development candidates are out-licensed to large pharmaceutical partners (notably Eli Lilly) for clinical development and commercialization.

Product overview

KeyBioscience is a biopharmaceutical company focused on discovering and developing novel peptide therapeutics for metabolic disorders. The company's core offering is its DACRA (Dual Amylin and Calcitonin Receptor Agonists) peptide platform, which leverages an extensive profiling platform inspired by naturally occurring peptide variants. The platform has yielded multiple product candidates: KBP-042 (first-generation for Type 2 Diabetes), KBP-089 and KBP-056 (for obesity and osteoarthritis), KBP-336 (long-acting once-weekly injectable for metabolic osteoarthritis currently in clinical development), and the Lilly-KeyBio QW DACRA (licensed to Eli Lilly for obesity). Three peptides have entered clinical development for Type 2 Diabetes, obesity, and osteoarthritis, with two licensed to Eli Lilly in 2017.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

  • KBP-336 is the most potent DACRA identified to date, selected for clinical development based on highly promising potency, stability, and durability of response in model systems

Companies that use KeyBioscience

Customer profile

Segments3 records

Ideal customer profiles1 record

KeyBioscience technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

KeyBioscience partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and minor.

  • Eli LillycoreStrategic or Co-development Partner · 1 January 2017Strategic partnership established in summer 2017 to develop the first Dual Amylin Calcitonin Receptor Agonist (DACRA) for type 2 diabetes as a once-daily injectable. KeyBioscience licensed two peptides (KBP-089 and KBP-056) to Eli Lilly. A second generation of the Lilly-KeyBio QW DACRA is now in clinical development for obesity. The partnership bore fruit with the announcement of the Lilly-KeyBio QW DACRA clinical asset in spring 2022.
  • Nordic BiosciencecoreStrategic or Co-development Partner · 1 January 2011Nordic Bioscience co-founded KeyBioscience (originally NUCo-Development) in October 2011 as an equal venture with Unigene. Nordic Bioscience provided financial support and has grown to be a partner to some of the largest drug developers in the world. Following Unigene's bankruptcy in 2013, Nordic Bioscience acquired Unigene's stake, transforming NUCo-Development into KeyBioscience.
  • UnigeneminorStrategic or Co-development Partner · 1 January 2011Original founding partner in NUCo-Development venture established October 2011 with Nordic Bioscience. Unigene contributed intellectual property to the partnership. Unigene faced bankruptcy in summer 2013, after which Nordic Bioscience acquired Unigene's stake.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

KeyBioscience competitors and assessment

Company assessment

Broad incumbents

  • Eli Lilly: Eli Lilly is KeyBioscience's strategic partner and the dominant incumbent in metabolic therapeutics, with the leading GLP-1/incretin franchise (tirzepatide) and its own obesity pipeline. Lilly provides the comparator benchmark for DACRA efficacy and the likely commercialization channel for licensed KeyBioscience assets.
  • Novo Nordisk: Novo Nordisk is the global incumbent in diabetes and obesity therapeutics, anchored by its GLP-1 franchise (semaglutide) and actively developing amylin and dual-agonist candidates. It defines the competitive bar that any DACRA-style therapy must clear to capture commercial value.

Emerging players

  • Rhythm Pharmaceuticals: Rhythm Pharmaceuticals is a commercial-stage company focused on rare metabolic diseases (MC4R pathway) with an MC4R agonist franchise. It shares with KeyBioscience a focus on peptide/receptor-agonist mechanisms targeting metabolic disease pathophysiology, although in a different receptor niche.
  • Vivani Medical: Vivani Medical (formerly Vivani + Cortigent) develops long-acting peptide-based implants for chronic metabolic disease. Its long-duration peptide delivery approach and metabolic indication focus intersect with KeyBioscience's once-weekly DACRA strategy for obesity and related disorders.
  • MBX Biosciences: MBX Biosciences is a clinical-stage peptide therapeutics company developing long-acting peptides for endocrine and metabolic disorders. Its emphasis on engineered, long-duration peptide analogs parallels KeyBioscience's prolonged-activation DACRA design philosophy.
  • Crinetics Pharmaceuticals: Crinetics is a clinical-stage company developing oral peptide/non-peptide agonists for endocrine and metabolic indications, including acromegaly and hyperinsulinism. Its peptide-based mechanism and metabolic/endocrine indication focus overlap directly with KeyBioscience's metabolic peptide strategy.

Direct peers

  • Zealand Pharma: Zealand Pharma is a clinical-stage peptide therapeutics company with a leading amylin analog program for obesity and metabolic disease, making it the closest direct competitor to KeyBioscience's DACRA platform in mechanism, indication space, and development stage.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

KeyBioscience compliance and trust

Trust signal

Compliance1 record

KeyBioscience financial estimates

Financial estimate

Revenue estimate

Valuation estimate

KeyBioscience leadership team

Management profile

Number of profiles

Profiles1 record

KeyBioscience funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

KeyBioscience M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about KeyBioscience

What does KeyBioscience do?

KeyBioscience is a clinical-stage biopharmaceutical company that discovers and develops novel peptide therapeutics for metabolic disorders. Its proprietary DACRA (Dual Amylin and Calcitonin Receptor Agonist) platform engineers peptides with prolonged receptor activation, enabling once-weekly injectable dosing for indications including Type 2 Diabetes, obesity, and metabolic osteoarthritis. Development candidates are out-licensed to large pharmaceutical partners (notably Eli Lilly) for clinical development and commercialization.

Is KeyBioscience a public or private company?

KeyBioscience is a private company. It is classified as corporate owned and is currently operating.

When was KeyBioscience founded?

KeyBioscience was founded in 2011. It employs 1 to 10 people.

Where is KeyBioscience based?

KeyBioscience is headquartered in Lugano, Switzerland, in the Europe region.

How does KeyBioscience make money?

Two revenue lines are on record. Licensing and Co-development Agreements are the primary driver. The others are strategic Partnerships.

Who are KeyBioscience's main competitors?

Broad incumbents on record are Eli Lilly and Novo Nordisk. Emerging players are Rhythm Pharmaceuticals, Vivani Medical, MBX Biosciences and Crinetics Pharmaceuticals. Zealand Pharma is listed as a direct peer.

Does KeyBioscience have an API?

No public API is recorded for KeyBioscience.

What industry is KeyBioscience in?

KeyBioscience's product category is Peptide Therapeutics for Metabolic Disorders. Its primary akta.pro industry code is HLAAAAAH, Therapeutic Peptides & Protein/Peptide Biologics, with a secondary code of HLAAAIAC, Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals